D&D Pharmatech Inc. (KOSDAQ:347850)

D&D Pharmatech Statistics

Total Valuation

D&D Pharmatech has a market cap or net worth of KRW 4.16 trillion. The enterprise value is 4.13 trillion.

Market Cap	4.16T
Enterprise Value	4.13T

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

D&D Pharmatech has 43.43 million shares outstanding. The number of shares has increased by 144.63% in one year.

Current Share Class	43.43M
Shares Outstanding	43.43M
Shares Change (YoY)	+144.63%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	20.64%
Owned by Institutions (%)	18.30%
Float	32.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	497.97
PB Ratio	55.62
P/TBV Ratio	92.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-118.91
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-168.99

Financial Position

The company has a current ratio of 9.82, with a Debt / Equity ratio of 0.09.

Current Ratio	9.82
Quick Ratio	8.74
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.27
Interest Coverage	-60.24

Financial Efficiency

Return on equity (ROE) is -47.71% and return on invested capital (ROIC) is -22.98%.

Return on Equity (ROE)	-47.71%
Return on Assets (ROA)	-19.54%
Return on Invested Capital (ROIC)	-22.98%
Return on Capital Employed (ROCE)	-34.37%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	-902.85M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +811.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+811.16%
50-Day Moving Average	67,617.00
200-Day Moving Average	35,357.38
Relative Strength Index (RSI)	62.75
Average Volume (20 Days)	1,682,991

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, D&D Pharmatech had revenue of KRW 8.36 billion and -34.76 billion in losses. Loss per share was -845.54.

Revenue	8.36B
Gross Profit	8.34B
Operating Income	-30.44B
Pretax Income	-36.58B
Net Income	-34.76B
EBITDA	-24.86B
EBIT	-30.44B
Loss Per Share	-845.54

Balance Sheet

The company has 37.94 billion in cash and 6.57 billion in debt, giving a net cash position of 31.37 billion or 722.35 per share.

Cash & Cash Equivalents	37.94B
Total Debt	6.57B
Net Cash	31.37B
Net Cash Per Share	722.35
Equity (Book Value)	74.88B
Book Value Per Share	6,954.78
Working Capital	40.59B

Cash Flow

In the last 12 months, operating cash flow was -24.26 billion and capital expenditures -198.62 million, giving a free cash flow of -24.45 billion.

Operating Cash Flow	-24.26B
Capital Expenditures	-198.62M
Free Cash Flow	-24.45B
FCF Per Share	-563.15

Margins

Gross Margin	99.68%
Operating Margin	-364.01%
Pretax Margin	-437.44%
Profit Margin	n/a
EBITDA Margin	-297.27%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

D&D Pharmatech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-144.63%
Shareholder Yield	-144.63%
Earnings Yield	-0.83%
FCF Yield	-0.59%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 13, 2025. It was a forward split with a ratio of 4.

Last Split Date	Nov 13, 2025
Split Type	Forward
Split Ratio	4

Scores

D&D Pharmatech has an Altman Z-Score of 23.65 and a Piotroski F-Score of 2.

Altman Z-Score	23.65
Piotroski F-Score	2